Febuxostat (TEI 6720) sodium has the potential in gout and hyperuricemia research which is a potent, selective and non-purine inhibitor of xanthine oxidase (XO) with a Ki value of 0.6 nM [1] [2] [3].

Febuxostat sodium exhibits potent mixed-type inhibition against purified bovine milk xanthine oxidase, demonstrating inhibitory effects on both the oxidized and reduced forms of the enzyme, as evidenced by K i and K i ' values of 0.6 nM and 3.1 nM, respectively [1].

Febuxostat sodium, at varying dosages and treatment durations, has been observed to significantly mitigate adverse conditions in several experimental models. Administered daily at 5-6 mg/kg for 4 weeks to rats on a high-fructose diet (60% fructose) for 8 weeks, it substantially lowers glomerular pressure, renal vasoconstriction, and the afferent arteriolar area as compared to rats on the same diet without febuxostat, yet it does not affect rats on a standard diet [2]. A lower dose (3-4 mg/kg, orally) combined with oxonic acid (750 mg/kg, orally) for 4 weeks effectively prevents renal injury in 5/6 nephrectomy rats, with or without hyperuricemia [3]. Additionally, at 2.5 mg/kg taken orally for 12 weeks, it inhibits plaque formation in ApoE / mice and reduces ROS levels in the aortic walls of these atherosclerotic mice [4]. A higher dose (15.6 mg/kg, orally, once daily for 21 consecutive days) displays an antidepressant effect by significantly reducing immobility time in the Forced Swim Test in mice [5]. Moreover, when combined with doxorubicin at 10 mg/kg, orally, for 21 days, it greatly decreases nephrotoxicity markers and inflammatory mediators, restores normal oxidative stress biomarker values, and reduces renal caspase-3 expression [6].